Authors
Latest:
[BLOG]: Obesity drug safety reviewIn this blog post, Robert Kyle of AdverseEvents compares the results of a postmarket survey of 3 obesity drugs.
Latest:
Major safety concerns with top-selling prescription drugsMajor safety concerns exist for many top-selling prescription drugs including benzodiazepines/prescription sleep aids, anticoagulants, cholesterol-lowering statins, oxycodone and hydrocodone, and stimulants. The following provides an overview of these classes and issues.
Latest:
Parkinson’s disease: Unmet needs to be fulfilled by novel therapies and reformulationsThe current global Parkinson’s disease market is characterized by a number of unmet needs, which include addressing the motor complications of dyskinesia and off-episodes. The recent approval of novel therapies and reformulations of existing drugs has the potential to fulfill some of these unmet needs, particularly in patients with advanced disease.
Latest:
[BLOG]: 5 reasons biosimilars must have distinguishable namesIn this blog response to the July 13 article "5 reasons to keep biosimilar names the same," Louis Tharp, executive director or Global Healthy Living Foundation, lists 5 reasons biosimilars must have distinguishable names.
Latest:
[BLOG]: 5 things you need to know about biosimilarsThe first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.
Latest:
Carflizomib: A second-generation proteasome inhibitor for the treatment of myelomaThe introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.
Latest:
New online tool available for Janssen productsJanssen Pharmaceuticals, Inc. is making it easier for pharmacists and healthcare professionals to look up drug information by launching an online scientific resource tool.
Latest:
Silicone Particles in Product Leads to Recall of TreprostinilOne lot of treprostinil injection is being recalled. Tresprostinil is a prostacyclin vasodilator used to treat patients with pulmonary arterial hypertension.
Latest:
Development of an adverse drug reaction bulletin in a teaching hospitalBulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions.
Latest:
Development of an adverse drug reaction bulletin in a teaching hospitalBulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions.
Latest:
Development of an adverse drug reaction bulletin in a teaching hospitalBulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Travoprost: A prostaglandin analogue for the treatment of glaucomaIn August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Latest:
Gingko biloba does not stop incidence of Alzheimer's disease, Lancet reportsThe long-term use of gingko biloba extract does not lower the risk of Alzheimer’s disease, according to a report published September 6 online for The Lancet.
Latest:
Dronedarone: An antiarrhythmic agent for the management of atrial fibrillation and atrial flutterDronedarone, an investigational antiarrhythmic agent being studied for the management of AF and atrial flutter, has a pharmacologic mechanism of action that is similar to that of amiodarone, but dronedarone lacks an iodine moiety, which may result in less thyroid and pulmonary toxicity. Dronedarone is currently pending FDA approval; the agent was granted priority review in August 2008.
Latest:
Review of antiretroviral agents for the treatment of HIV infectionThe challenge of controlling HIV in patients with resistance to antiretrovirals has contributed to accelerated research into treatments with novel antiretroviral activity.
Latest:
Review of antiretroviral agents for the treatment of HIV infectionThe challenge of controlling HIV in patients with resistance to antiretrovirals has contributed to accelerated research into treatments with novel antiretroviral activity.
Latest:
The Academy of Managed Care Pharmacy's 24th Annual Meeting and Showcase: Specialty pharmaceutical pipeline rich with multiple sclerosis, rheumatoid arthritis, hepatitis C, cancer agentsForecasts from AMCP's annual meeting indicate a full pipeline for specialty medications.
Latest:
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safetyEslicarbazepine acetate (eslicarbazepine, or ESL) is a new antiepileptic agent awaiting FDA approval.
Latest:
Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseasesGolimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
